Khamis Al-Hashmi1, Ibrahim Al-Zakwani2, Wael Al Mahmeed3, Mohammed Arafah4, Ali T Al-Hinai5, Abdullah Shehab6, Omer Al Tamimi7, Mahmoud Al Awadhi8, Shorook Al Herz9, Faisal Al Anazi10, Khalid Al Nemer11, Othman Metwally12, Akram Alkhadra13, Mohammed Fakhry13, Hossam Elghetany14, Abdel Razak Medani15, Afzal Hussein Yusufali15, Obaid Al Jassim15, Omar Al Hallaq16, Fahad Omar Ahmed S Baslaib17, Haitham Amin18, Raul D Santos19, Khalid Al-Waili20, Khalid Al-Rasadi21. 1. Department of Physiology, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. 2. Department of Pharmacology & Clinical Pharmacy, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman; Gulf Health Research, Muscat, Oman. 3. Heart and Vascular Institute -Cleveland Clinic, Abu Dhabi, UAE. 4. King Saud University Hospital, Riyadh, KSA. 5. Ministry of Health, Muscat, Oman. 6. UAE University, AlAin, UAE. 7. Hamad Medical Corporation, Doha, Qatar. 8. Al Amiri Hospital, Kuwait City, Kuwait. 9. King Fahad National Guard Hospital, Riyadh, KSA. 10. Ministry of Health, Riyadh, KSA. 11. Al-Imam Mohammad Ibn Saud Islamic University (IMSIU), School of Medicine, Riyadh, KSA. 12. King Fahad General Hospital, Jeddah, KSA. 13. King Fahad Hospital of the University, Khobar, KSA. 14. Soliman Fakieh Hospital, Jeddah, KSA. 15. Dubai Hospital, Dubai, UAE. 16. American Hospital, Dubai, UAE. 17. Rashid Hospital, Dubai, UAE. 18. Bahrain Defense Force Hospital, Manama, Bahrain. 19. Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil. 20. Department of Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman. 21. Department of Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman. Electronic address: k.alrasadi@gmail.com.
Abstract
BACKGROUND: Atherogenic dyslipidemia is highly prevalent in the Arabian Gulf. Non-high-density lipoprotein cholesterol (non-HDL-C) reduction has been proposed as an additional goal to low-density lipoprotein cholesterol (LDL-C) lowering to prevent atherosclerotic cardiovascular disease (ASCVD). Data on non-HDL-C goal attainment in patients with high triglycerides (TGs) on lipid-lowering drugs (LLDs) in the region is scarce. OBJECTIVE: Evaluate non-HDL-C target attainment according to the National Lipid Association in patients on LLDs stratified by TG (<150 [1.69], 150-200 [1.69-2.26], >200 [2.26] mg/dL [mmol/L]) levels in the Arabian Gulf. METHODS: Overall, 4383 patients on LLD treatment from 6 Middle Eastern countries participating in the Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia study were evaluated. Patients were classified according to TG levels and ASCVD risk. RESULTS: The overall non-HDL-C goal attainment was 41% of the subjects. Non-HDL-C goal was less likely attained in patients with high TGs (12% vs 27% vs 55%; P < .001). Very high ASCVD risk patients with high TGs attained less their non-HDL-C targets compared with those with lower TG levels (8% vs 23% vs 51%; P < .001). Similarly, high ASCVD risk patients with high TGs also failed more in attaining non-HDL-C targets compared with those with lower TGs (26% vs 42% vs 69%; P < .001). In addition, those with high TG also succeeded less in attaining LDL-C and apolipoprotein B goals (P < .001). CONCLUSIONS: A large proportion of very high and high ASCVD patients on LLDs in the Arabian Gulf are not at recommended non-HDL-C targets and hence remain at a substantial residual risk.
BACKGROUND: Atherogenic dyslipidemia is highly prevalent in the Arabian Gulf. Non-high-density lipoprotein cholesterol (non-HDL-C) reduction has been proposed as an additional goal to low-density lipoprotein cholesterol (LDL-C) lowering to prevent atherosclerotic cardiovascular disease (ASCVD). Data on non-HDL-C goal attainment in patients with high triglycerides (TGs) on lipid-lowering drugs (LLDs) in the region is scarce. OBJECTIVE: Evaluate non-HDL-C target attainment according to the National Lipid Association in patients on LLDs stratified by TG (<150 [1.69], 150-200 [1.69-2.26], >200 [2.26] mg/dL [mmol/L]) levels in the Arabian Gulf. METHODS: Overall, 4383 patients on LLD treatment from 6 Middle Eastern countries participating in the Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia study were evaluated. Patients were classified according to TG levels and ASCVD risk. RESULTS: The overall non-HDL-C goal attainment was 41% of the subjects. Non-HDL-C goal was less likely attained in patients with high TGs (12% vs 27% vs 55%; P < .001). Very high ASCVD risk patients with high TGs attained less their non-HDL-C targets compared with those with lower TG levels (8% vs 23% vs 51%; P < .001). Similarly, high ASCVD risk patients with high TGs also failed more in attaining non-HDL-C targets compared with those with lower TGs (26% vs 42% vs 69%; P < .001). In addition, those with high TG also succeeded less in attaining LDL-C and apolipoprotein B goals (P < .001). CONCLUSIONS: A large proportion of very high and high ASCVD patients on LLDs in the Arabian Gulf are not at recommended non-HDL-C targets and hence remain at a substantial residual risk.
Authors: Li-Ling Guo; Yan-Qiao Chen; Qiu-Zhen Lin; Feng Tian; Qun-Yan Xiang; Li-Yuan Zhu; Jin Xu; Tie Wen; Ling Liu Journal: Front Cardiovasc Med Date: 2021-04-01
Authors: Hilal Al-Sabti; Ali T Al-Hinai; Ibrahim Al-Zakwani; Khamis Al-Hashmi; Wael Al Mahmeed; Mohamed Arafah; Abdullah Shehab; Omer Al Tamimi; Mahmoud Al Awadhi; Shorook Al Herz; Faisal Al Anazi; Khalid Al Nemer; Othman Metwally; Akram Alkhadra; Mohammed Fakhry; Hossam Elghetany; Abdel Razak Medani; Afzal Hussein Yusufali; Obaid Al Jassim; Omar Al Hallaq; Fahad Omar Ahmed S Baslaib; Haitham Amin; Khalid Al-Waili; Khalid Al-Rasadi Journal: Oman Med J Date: 2022-03-22